Objectives: To analyze the expression of E-cadherin and b-catenin in triple-negative breast cancer (TNBC) to assess their prognostic significance.
Results: Of 72 consecutive TNBCs, 56% showed reduced membranous expression of E-cadherin or b-catenin, with a strong correlation to each other. Of the clinicopathologic factors analyzed, tumor size and nodal status were significantly associated with overall survival and disease-specific survival, while the latter remained an independent factor by multivariate analysis. Reduced E-cadherin and b-catenin were both significantly associated with a poor overall survival and disease-specific survival by univariate and multivariate analyses.
Conclusions: E-cadherin and b-catenin expression provides discriminative prognostic power independent of conventional pathologic factors, thus further reinforcing the important role of cell adhesion molecules in the process of tumor metastasis, especially in TNBC.
Breast cancer is a complex, heterogeneous disease consisting of different subgroups on the histopathologic, molecular, and clinical levels with diverse prognostic outcomes and therapeutic implications. While 70% to 80% of breast cancers overexpress hormonal receptors (estrogen receptor [ER] and progesterone receptor [PR] ), approximately 15% to 20% of tumors demonstrate human epidermal growth factor receptor 2 (HER2) gene amplification and/or protein overexpression. 1 Triple-negative breast cancer (TNBC), defined by the absence of detectable ER and PR expression and the lack of HER2 amplification/overexpression, constitutes approximately 15% to 26% of all breast cancers and represents an aggressive clinical phenotype. 2, 3 Patients harboring TNBC do not benefit from endocrine therapy or HER2-targeted therapy with trastuzumab. Cytotoxic chemotherapy is currently the only treatment modality.
Upon completion of this activity you will be able to:
• describe the role of the E-cadherin/b-catenin complex in mammary epithelial integrity.
• outline what is currently known about the role of the E-cadherin and b-catenin in the epithelial-mesenchymal transition.
• recognize the prognostic significance of E-cadherin and b-catenin in triple-negative breast cancer.
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Furthermore, more than 50% of TNBCs do not respond to systemic chemotherapy, and those without a pathologic complete response have a high likelihood of local recurrence and frequent distant metastasis. Distant relapse drastically worsens the prognostic outcome, as 90% of breast cancer mortality is the result of metastasis at distant organs that are resistant to adjuvant therapies. 4 Therefore, identification of novel prognostic markers would allow a better characterization of this subgroup of breast cancers and aid in therapeutic decisions. E-cadherin is a transmembrane glycoprotein that mediates calcium-dependent cell-to-cell adhesion fundamentally important to the generation of a polarized epithelial phenotype. The intracellular region of the molecule contains binding sites to interact with catenins and other regulatory proteins. The E-cadherin/b-catenin complex plays an essential role in maintaining epithelial integrity. Aberrant expression and disruption of this complex affect the adhesive repertoire of a cell and are associated with a variety of malignancies resulting from a process known as the epithelial-mesenchymal transition (EMT).
Under normal conditions, these molecules are expressed in the cytoplasmic membrane of epithelial cells. The cytoplasmic domains of E-cadherin interact with b-catenin, and this reciprocal action is crucial to the adhesive function of E-cadherin. However, under pathologic conditions such as cancer, the interaction between cytoplasmic domains of E-cadherin and b-catenin may be destroyed, leading to impairment of cell-cell adhesion. The free cytoplasmic b-catenin may translocate into the nucleus and activate the Wnt signaling pathway, which contributes to tumorigenesis and progression in many organ systems, including the breast. Based on its biological functions, Ecadherin is regarded as an invasion and metastasis suppressor. 5 Studies have shown that aberrant expression of E-cadherin and b-catenin correlates with increased invasion and metastasis in a number of human cancers, including breast carcinoma. It is well known that loss of E-cadherin expression is a characteristic histopathologic feature of lobular breast cancer. However, recent studies have suggested that reduced E-cadherin expression may be associated with distant metastasis and poor outcomes of nonlobular breast cancers. 5, 6 On the other hand, aberrant cytoplasmic/nuclear expression of b-catenin has also been found to correlate with poor prognosis in patients with breast cancer. [7] [8] [9] However, the observations on the prognostic values of Ecadherin and b-catenin in TNBC are limited or inconsistent. Moreover, simultaneous studies of both proteins in TNBC are even rarer in the literature. In this study, we sought to examine the expression patterns of E-cadherin and b-catenin in TNBC and to evaluate their prognostic significance in this subset of aggressive breast cancers.
Materials and Methods
After approval by the University of Alabama at Birmingham (UAB) Institutional Review Board, the UAB Tumor Registry was searched to identify invasive breast cancer cases with a TNBC phenotype between January 1, 1998, and December 31, 2014. The clinicopathologic parameters, including age, race, tumor type, histologic grade, and pathologic tumor and nodal stages, along with the patients' survival outcomes, were recorded. The accuracy of the data was further verified for each patient using the electronic medical record and surgical pathology database. The H&E-stained sections of prechemotherapy tumoral tissue were reviewed by the authors (T.S. and S.W.). Patients with a diagnosis of pleomorphic lobular carcinoma, those with distant metastases at diagnosis, those who received no treatment, and those lost to follow-up were excluded from the study. This led to a total of 72 cases meeting the inclusion criteria.
Evaluation of ER and PR expression was performed by immunohistochemistry, and HER2 status was assessed by immunohistochemistry or in situ hybridization analysis at the time of diagnosis, as previously described. 10 A positive ER or PR was defined as 1% or more of tumor cells with nuclear immunoreactivity. HER2 overexpression was determined as uniform and intense membranous staining of more than 30% of tumor cells, while HER2 gene amplification was defined as a positive in situ hybridization result.
Immunohistochemical Detection of E-Cadherin and b-Catenin
E-cadherin and b-catenin expression was assessed by immunohistochemistry according to the manufacturer's protocols. Briefly, 4-mm sections were obtained from formalin-fixed, paraffin-embedded block preparations. Heatinduced epitope retrieval with a 0.02 mol/L concentration of citrate buffer (pH 6.0) in a heater at 120 C for 20 minutes was applied. The sections were incubated for 20 minutes at room temperature with a predilute mouse anti-human E-cadherin monoclonal antibody (clone 36; Ventana, Tucson, AZ) or a predilute mouse anti-human b-catenin monoclonal antibody (clone b-catenin 1; Dako, Carpinteria, CA). The immunostaining was accomplished with a semiautomated immunostainer (Ventana) using an ultraView (Ventana) horseradish peroxidase multimer approach. The chromogen diaminobenzidine tetrachloride was used to visualize the antibody-antigen complex. The section was counterstained with hematoxylin. The tissue known to express the protein of interest was used as a positive control, whereas the negative control was prepared by replacing the primary antibodies by a nonimmune immunoglobulin of the same isotype. Since normal mammary epithelial cells express E-cadherin and b-catenin in a membranous fashion, benign ductal epithelium present in the tumor sections was used as the internal control. The intensity of membranous E-cadherin or b-catenin in tumor cells was scored as 3 (intensity more than two-thirds of that of adjacent normal epithelium), 2 (one-third to two-thirds), 1 (less than onethird), or 0 (no staining). A score of 2 or less was regarded as reduced expression. Cytoplasmic/nuclear subcellular localization of b-catenin was also examined.
Statistical Analysis
The categorical data were evaluated using either the v 2 test or the Fisher exact test, as appropriate, while the continuous variables obtained were analyzed using the Student t test. Overall survival (calculated from the date of diagnosis to the date of death from any cause or the follow-up cutoff) and disease-specific survival (from the date of diagnosis to the date of death from disease) were plotted on Kaplan-Meier curves. Patients who survived or were lost to follow-up were considered censored data in the analysis. The log-rank test was used to compare groups, followed by performance of a Cox proportional hazards regression analysis. A P value of .05 or less was considered statistically significant. The statistical analysis was conducted using GraphPad Prism 6 (GraphPad Software, La Jolla, CA) and the R.3.0.1 (www.r-project.org) software.
Results

Clinicopathologic Characteristics
The demographic information of the 72 patients included in the study and pathologic characteristics of the primary tumors are summarized in Table 1 . In brief, both the mean and median ages were 56 years (range, 29-84 years). Most of these tumors were invasive carcinoma of no special type and were of predominantly high histologic grade. A significant proportion of these tumors were also of high pathologic stage, thus reflecting the unfavorable clinical outcome of these patients. The mean and median follow-up times were 46 and 35 months, respectively. Twenty-six patients died during follow-up, of whom 22 died of disease.
E-Cadherin and b-Catenin Expression in TNBC
Strong membranous expression of E-cadherin and b-catenin was consistently seen in the normal mammary epithelial cells. However, compared with the intensity of staining in adjacent normal duct epithelium, reduced membranous E-cadherin and b-catenin expression was observed in 40 (56%) and 40 (56%) TNBC cases, respectively, as illustrated in Image 1 and Image 2 . No case demonstrated a complete loss of E-cadherin or b-catenin membranous expression. There was a strong correlation of the expression levels between the two molecules (R ¼ 0.82; P <0.0001). Two tumors with intact E-cadherin showed reduced membranous b-catenin, whereas two cases with intact b-catenin demonstrated reduced membranous E-cadherin. Of the 40 cases with reduced membranous b-catenin, cytoplasmic localization of the protein was found in four (10%) cases (Image 2D), while nuclear translocation was not observed in any case. The intensity of membranous E-cadherin or b-catenin was not significantly correlated with other clinicopathologic factors analyzed (data not shown).
Factors Associated With Survival Outcomes
Among the clinicopathologic factors included, the logrank test revealed that tumor size/pathologic tumor stage and nodal status were significantly associated with overall and disease-specific survival, respectively, by univariate analysis Table 2 . As expected, small tumor size/low pathologic tumor stage was associated with a significantly favorable clinical outcome. No significant difference for overall or disease-specific survival was observed between pT1 and pT2 tumors. Likewise, the presence of positive axillary lymph nodes was associated with a significantly increased hazard of death. Age, race, and histologic grade were not significantly associated with survival outcomes. The prognostic significance of E-cadherin and b-catenin expression was evaluated. To that end, reduced membranous E-cadherin and b-catenin was significantly associated with both a worse overall and disease-specific survival in this cohort (Table 2) Figure 1 and Figure 2 . Moreover, nodal status, E-cadherin, and b-catenin remained prognostically significant by multivariate analysis while tumor size/pathologic tumor stage was not an independent prognostic factor Table 3 . Given the strong correlation of E-cadherin and b-catenin expression, they were statistically significant when either of the two variables was included in the Cox proportional hazards model, but not both, thus further attesting to their function as a complex in maintaining epithelial integrity. Furthermore, similar results were obtained when only including the invasive carcinomas of no special type (n ¼ 67, data not shown).
Discussion
While TNBC usually possesses unfavorable pathologic features, including high histologic grade, large tumor size, and a higher frequency of positive axillary lymph nodes at presentation, 3 ,11 a substantial degree of uncertainty and controversy remains with respect to the reported prognostic factors in TNBC. Of the putative clinicopathologic prognostic factors analyzed in this cohort, tumor size and nodal status were prognostically significant, in keeping with most published studies. [12] [13] [14] The histologic grade was not prognostically significant in our analysis, in harmony with a recent report, 14 most likely because most TNBC cases are of high grade, as seen in the current study. We found that E-cadherin and b-catenin, two closely related cell-cell adhesion molecules, were independent prognostic factors in TNBC. CI, confidence interval; HR, hazard ratio. a E-cadherin and b-catenin are highly correlated variables and thus are statistically significant for overall and disease-specific survival when either one is included in the model, but not both.
Downregulation of E-cadherin is a hallmark of the EMT, an essential step in the metastatic progression of human cancer. 15 Reduced E-cadherin expression was a frequent event in breast cancer and was observed in 41.5% of invasive, nonlobular carcinomas. 5 A loss of E-cadherin was associated with larger tumor size, higher histologic grade, and lymph node metastasis. 6, 16 Further, E-cadherin reduction was more profound in TNBC and was observed in 42% to 73% of such cases. 3, 5, [17] [18] [19] [20] However, there have been inconsistent findings with regard to the prognostic significance of E-cadherin in TNBC. Negative E-cadherin, either by itself or in combination with other biomarkers (androgen receptor positivity or a high Ki-67 proliferation index), was a significant unfavorable prognostic factor. [19] [20] [21] In contrast, negative E-cadherin was not associated with lymphatic invasion, distant metastasis, or survival outcomes in other cohort studies. 17, 22, 23 On the other hand, aberrant cytoplasmic/nuclear expression of b-catenin in breast cancer cells has been reportedly associated with a poorer prognosis, suggesting that activation of Wnt signaling plays a key role in tumor progression. [7] [8] [9] 24 Enriched nuclear and cytosolic accumulation of b-catenin was found in basal-like carcinomas, which are typically of a TNBC phenotype. 25 Lack/reduction of b-catenin membranous expression, as a result of disassociation of the molecule from E-cadherin and impaired cell-cell adhesion, and/or nuclear accumulation were significantly associated with lack/reduction of E-cadherin expression, a TNBC phenotype, and adverse outcomes in nonlobular cancers. 26 In the latter study, 55% and 48% of the TNBCs displayed reduced b-catenin membranous expression and nuclear accumulation, respectively. 26 Moreover, a recent study detected a much higher proportion (79%) of the TNBC cases exhibiting reduced membranous or positive cytoplasmic/nuclear staining of bcatenin, and this aberrant b-catenin expression was significantly associated with adverse outcomes. However, no difference of b-catenin expression was found among different breast cancer subtypes. 27 In the current study, 40% and 40% of TNBC cases showed reduced membranous E-cadherin and b-catenin expression, respectively, with a significantly strong correlation with each other, except for four (5%) tumors, in keeping with previous reports. 26, 28 Interestingly, expression of these molecules was not related to histologic grade, lymph node status, or other clinicopathologic parameters, in agreement with selected investigations. 18, 21, 22 While association of b-catenin expression and histologic grade was documented in a recent cohort study, 29 the latter also included ductal carcinomas other than TNBC. Importantly, the two adhesion molecules were both independent prognostic factors in the current study, thus mostly consistent with early studies examining TNBC. 18, 19, 26, 27 It is also noteworthy that TNBC with E-cadherin expression was found to have a higher chemoresponse than TNBC without E-cadherin expression in all chemotherapeutic agents studied. 30 Taken together, these results support the notion that E-cadherin can be used as a prognostic marker in the management of patients with TNBC. The exact mechanism underlying the reduced E-cadherin in breast cancer remains to be elucidated. The proposed potential molecular basis includes hypermethylation of the E-cadherin promoter, inactivation of the gene by mutation, loss of heterozygosity, or transcription suppression. [31] [32] [33] With regard to the subcellular localization of b-catenin, only four (5%) of 72 TNBCs demonstrated cytoplasmic expression, and no nuclear expression was observed in any cases in this cohort, in contrast to two previous studies with smaller sample sizes. 26, 27 The reason for this discrepancy is unclear but might be due to different antibody clones and/or tumor compositions. For example, an aforementioned study found that the cytoplasmic/nuclear expression of b-catenin was more prevalent in metaplastic carcinomas for which the EMT plays a crucial role in the pathogenesis, 26 whereas only three metaplastic carcinomas
were included in the current study. It should be acknowledged that immunohistochemical semiquantitation of protein expression levels is subjective, an inherent weakness of all such studies. In this study, the intensity of expression in the normal epithelia of the same tumor section was used as an internal control (3þ) to maximally overcome the variability. In addition, the use of large tissue sections in the study was thought to better represent the expression levels of the protein compared with some other studies using tissue microarrays, as heterogeneity is a chief characteristic of breast cancer.
In summary, our study provides additional evidence that the expression levels of the two closely related molecules, E-cadherin and b-catenin, are of discriminative prognostic value, thus further reinforcing the important role of cell adhesion molecules in breast cancer progression. While it has not risen to the level where routine testing of these markers is needed in clinical practice, the collective findings thus far suggest that targeting the key cell adhesion molecules deserves further investigation to unravel potential novel therapeutic targets to prevent metastatic dissemination of breast cancer in the pursuit of precision medicine. This is especially important in TNBC, for which no proven targeted therapy is available and the only systemic treatment is cytotoxic chemotherapy.
